TY - JOUR
T1 - ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer
AU - Hong, Xin
AU - Michalski, Christoph W.
AU - Kong, Bo
AU - Zhang, Weiwei
AU - Raggi, Matthias C.
AU - Sauliunaite, Danguole
AU - De Oliveira, Tiago
AU - Friess, Helmut
AU - Kleeff, Jörg
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Aims: Cell-cell adhesion is a major factor in integrity of epithelia which is frequently disturbed in cancer leading to local invasion and distant metastasis. Methods: To define expression and function of activated leukocyte cell adhesion molecule (ALCAM, CD166) in pancreatic cancer and in pancreatic neuroendocrine tumors (PNET), microarray analyses, RT-PCR, immunohistochemistry, RNAi, adhesion, migration, invasion, and chemoresistance assays were used. Results: We demonstrate that expression of ALCAM is altered and its serum levels are increased in pancreatic ductal adenocarcinoma (PDAC). ALCAM was expressed on the membranes of islet cells in the normal pancreas whereas normal pancreatic ducts were ALCAM-negative. In PDAC, ALCAM expression was generally rare though in some tumors, membranous, or cytoplasmic ALCAM was found. PNET were mostly ALCAM-positive with a cytoplasmic staining pattern which was in contrast to the membrane expression observed in non-transformed islet cells. In vitro, ALCAM silencing using RNAi had no effects on growth or invasion of pancreatic cancer cells but reduced cell adhesion and induced chemoresistance. In neuroendocrine tumor cell lines, silencing of ALCAM decreased cell growth. Conclusions: We propose ALCAM as a novel serum biomarker in human pancreatic tumors which is associated with cell adhesion, growth and chemoresistance.
AB - Aims: Cell-cell adhesion is a major factor in integrity of epithelia which is frequently disturbed in cancer leading to local invasion and distant metastasis. Methods: To define expression and function of activated leukocyte cell adhesion molecule (ALCAM, CD166) in pancreatic cancer and in pancreatic neuroendocrine tumors (PNET), microarray analyses, RT-PCR, immunohistochemistry, RNAi, adhesion, migration, invasion, and chemoresistance assays were used. Results: We demonstrate that expression of ALCAM is altered and its serum levels are increased in pancreatic ductal adenocarcinoma (PDAC). ALCAM was expressed on the membranes of islet cells in the normal pancreas whereas normal pancreatic ducts were ALCAM-negative. In PDAC, ALCAM expression was generally rare though in some tumors, membranous, or cytoplasmic ALCAM was found. PNET were mostly ALCAM-positive with a cytoplasmic staining pattern which was in contrast to the membrane expression observed in non-transformed islet cells. In vitro, ALCAM silencing using RNAi had no effects on growth or invasion of pancreatic cancer cells but reduced cell adhesion and induced chemoresistance. In neuroendocrine tumor cell lines, silencing of ALCAM decreased cell growth. Conclusions: We propose ALCAM as a novel serum biomarker in human pancreatic tumors which is associated with cell adhesion, growth and chemoresistance.
KW - Adhesion
KW - ALCAM
KW - Chemoresistance
KW - Invasion
KW - Migration
KW - Pancreatic cancer
KW - Pancreatic endocrine tumors
UR - http://www.scopus.com/inward/record.url?scp=77952046397&partnerID=8YFLogxK
U2 - 10.1002/jso.21538
DO - 10.1002/jso.21538
M3 - Article
C2 - 20461761
AN - SCOPUS:77952046397
SN - 0022-4790
VL - 101
SP - 564
EP - 569
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 7
ER -